{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:20:39Z","timestamp":1777378839274,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>\n                    The objective of this study was to assess the patterns of genotypic and phenotypic resistance in a population of blood donor patients infected with HIV-1 subtype B\u2032 (Thai B\u2032, a clade of HIV-1 B) from central China, previously treated and harboring NRTI and NNRTI resistance mutations, with the purpose of designing effective therapeutic regimens. The HIV-1\n                    <jats:italic toggle=\"yes\">pol<\/jats:italic>\n                    genes from 65 patients were sequenced and estimated for drug resistance while the viruses isolated from the patients were used to analyze the phenotype based on the TZM-bl cell line. All the HIV-1 strains harboring one or more drug resistance mutations to HIV-1 RTIs possessed high cross-resistance to EFV (100%) and DLV (92%), as well as to ABC (84%) and TDF (77%), which are much higher than both FTC and 3TC (42%). There were more thymidine analog mutation (TAM)-associated mutations in the AZT\/ddI\/NVP group (62.5%) than in the d4T\/ddI\/NVP group (32.65%). A phenotypic assay showed high concordance between genotypic and phenotypic cross-resistance. This study showed there was a high level of cross-drug resistance to HIV-1 RTIs among Chinese AIDS patients harboring resistant strains, and there is also a high prevalence of primary resistance to 3TC, suggesting that one important recommendation should be the realization of genotypes in all naive patients due to the high prevalence of NRTI and NNRTI mutations.\n                  <\/jats:p>","DOI":"10.1089\/aid.2009.0252","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T12:39:16Z","timestamp":1282135156000},"page":"1007-1013","source":"Crossref","is-referenced-by-count":14,"title":["Genotypic and Phenotypic Cross-Drug Resistance of Harboring Drug-Resistant HIV Type 1 Subtype B\u2032 Strains from Former Blood Donors in Central Chinese Provinces"],"prefix":"10.1177","volume":"26","author":[{"given":"Liying","family":"Ma","sequence":"first","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghong","family":"Huang","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xing","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Yu","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]},{"name":"Southern Medical University","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Sun","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Huang","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiling","family":"Qu","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjie","family":"Liao","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Liu","sequence":"additional","affiliation":[{"name":"Southern Medical University","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Shao","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention (NCAIDS)","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,9,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92698-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290354"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/590945"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-3-87"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/135965350000500112"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200103011-00006"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290356"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2008.361"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.9.7368-7375.1999"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.4.2855-2864.1998"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000243049.27580.cc"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(03)00082-9"},{"key":"e_1_3_3_14_2","first-page":"A59","article-title":"Identification of lamivudine (3TC) as a novel substrate for human organic cation transporters 1, 2 and 3","volume":"13","author":"Minuesa G","year":"2008","unstructured":"Minuesa G, , Volk C, , Gorboulev V et al. Identification of lamivudine (3TC) as a novel substrate for human organic cation transporters 1, 2 and 3. Antiviral Ther, 2008; 13:A59(Abstract No. 54).","journal-title":"Antiviral Ther"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.2.335-340.2002"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/319231"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbn017"},{"key":"e_1_3_3_18_2","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1","volume":"16","author":"Johnson VA","year":"2008","unstructured":"Johnson VA, , Brun-Vezinet F, , Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med, 2008; 16:138\u2013145.","journal-title":"Top HIV Med"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-6-45"},{"issue":"2","key":"e_1_3_3_20_2","first-page":"67","article-title":"HIV-1 drug resistance mutations: An updated framework for the second decade of HAART","volume":"10","author":"Shafer RW","year":"2008","unstructured":"Shafer RW, , Schapiro JM. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev, 2008; 10,2:67\u201384.","journal-title":"AIDS Rev"},{"key":"e_1_3_3_21_2","unstructured":"DHHS: Guidelines for the Use of Antiretroviral Agents in HIV-1\u2013Infected Adults and Adolescents. http:\/\/aidsinfor.nih.gov. 2006 May 18."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000196177.65551.ea"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328013caff"},{"key":"e_1_3_3_24_2","first-page":"S111","article-title":"Impact and evolution of resistance in patients treated by a salvage regimen combining amprenavir, lopinavir and ritonavir (the puzzle 1 study)","volume":"7","author":"Droz C","year":"2002","unstructured":"Droz C, , Morand-Joubert L, , Raguin G. Impact and evolution of resistance in patients treated by a salvage regimen combining amprenavir, lopinavir and ritonavir (the puzzle 1 study) Antiviral Ther, 2002; 7:S111.","journal-title":"Antiviral Ther"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2009.0252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2009.0252","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2009.0252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:12:26Z","timestamp":1777367546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/aid.2009.0252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1089\/aid.2009.0252"],"URL":"https:\/\/doi.org\/10.1089\/aid.2009.0252","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}